Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 11

1.

Effects of Vedolizumab in Patients with Primary Sclerosing Cholangitis and Inflammatory Bowel Diseases.

Lynch KD, Chapman RW, Keshav S, Montano-Loza AJ, Mason AL, Kremer AE, Vetter M, de Krijger M, Ponsioen CY, Trivedi P, Hirschfield G, Schramm C, Liu CH, Bowlus CL, Estes DJ, Pratt D, Hedin C, Bergquist A, de Vries AC, Janneke van der Woude C, Yu L, Assis DN, Boyer J, Ytting H, Hallibasic E, Trauner M, Marschall HU, Daretti LM, Marzioni M, Yimam KK, Perin N, Floreani A, Beretta-Piccoli BT, Rogers JK; International Primary Sclerosing Cholangitis Study Group (IPSCSG), Levy C.

Clin Gastroenterol Hepatol. 2019 May 14. pii: S1542-3565(19)30523-3. doi: 10.1016/j.cgh.2019.05.013. [Epub ahead of print]

2.

The Use of Biologics in Patients with Inflammatory Bowel Disease and Primary Sclerosing Cholangitis.

Lynch KD, Keshav S, Chapman RW.

Curr Hepatol Rep. 2019;18(1):115-126. doi: 10.1007/s11901-019-00456-2. Epub 2019 Mar 7. Review.

3.

Nonalcoholic fatty liver disease alters microcystin-LR toxicokinetics and acute toxicity.

Clarke JD, Dzierlenga A, Arman T, Toth E, Li H, Lynch KD, Tian DD, Goedken M, Paine MF, Cherrington N.

Toxicon. 2019 Apr 15;162:1-8. doi: 10.1016/j.toxicon.2019.03.002. Epub 2019 Mar 5.

PMID:
30849452
4.

Factors Associated With Outcomes of Patients With Primary Sclerosing Cholangitis and Development and Validation of a Risk Scoring System.

Goode EC, Clark AB, Mells GF, Srivastava B, Spiess K, Gelson WTH, Trivedi PJ, Lynch KD, Castren E, Vesterhus MN, Karlsen TH, Ji SG, Anderson CA, Thorburn D, Hudson M, Heneghan MA, Aldersley MA, Bathgate A, Sandford RN, Alexander GJ, Chapman RW, Walmsley M; UK-PSC Consortium, Hirschfield GM, Rushbrook SM.

Hepatology. 2019 May;69(5):2120-2135. doi: 10.1002/hep.30479. Epub 2019 Mar 4.

5.

Clinical Acquired Resistance to RAF Inhibitor Combinations in BRAF-Mutant Colorectal Cancer through MAPK Pathway Alterations.

Ahronian LG, Sennott EM, Van Allen EM, Wagle N, Kwak EL, Faris JE, Godfrey JT, Nishimura K, Lynch KD, Mermel CH, Lockerman EL, Kalsy A, Gurski JM Jr, Bahl S, Anderka K, Green LM, Lennon NJ, Huynh TG, Mino-Kenudson M, Getz G, Dias-Santagata D, Iafrate AJ, Engelman JA, Garraway LA, Corcoran RB.

Cancer Discov. 2015 Apr;5(4):358-67. doi: 10.1158/2159-8290.CD-14-1518. Epub 2015 Feb 11.

6.

Anchored multiplex PCR for targeted next-generation sequencing.

Zheng Z, Liebers M, Zhelyazkova B, Cao Y, Panditi D, Lynch KD, Chen J, Robinson HE, Shim HS, Chmielecki J, Pao W, Engelman JA, Iafrate AJ, Le LP.

Nat Med. 2014 Dec;20(12):1479-84. doi: 10.1038/nm.3729. Epub 2014 Nov 10.

PMID:
25384085
7.

Identification of oncogenic mutations and gene fusions in the follicular variant of papillary thyroid carcinoma.

McFadden DG, Dias-Santagata D, Sadow PM, Lynch KD, Lubitz C, Donovan SE, Zheng Z, Le L, Iafrate AJ, Daniels GH.

J Clin Endocrinol Metab. 2014 Nov;99(11):E2457-62. doi: 10.1210/jc.2014-2611. Epub 2014 Aug 22.

8.

Recurrent die-offs of adult coho salmon returning to spawn in Puget Sound lowland urban streams.

Scholz NL, Myers MS, McCarthy SG, Labenia JS, McIntyre JK, Ylitalo GM, Rhodes LD, Laetz CA, Stehr CM, French BL, McMillan B, Wilson D, Reed L, Lynch KD, Damm S, Davis JW, Collier TK.

PLoS One. 2011;6(12):e28013. doi: 10.1371/journal.pone.0028013. Epub 2011 Dec 14.

9.

MMPI-A validity scale uses and limitations in detecting varying levels of random responding.

Archer RP, Handel RW, Lynch KD, Elkins DE.

J Pers Assess. 2002 Jun;78(3):417-31.

PMID:
12146812
10.

The effectiveness of MMPI-A items in discriminating between normative and clinical samples.

Archer RP, Handel RW, Lynch KD.

J Pers Assess. 2001 Dec;77(3):420-35. Erratum in: J Pers Assess 2002 Oct;79(2):375.

PMID:
11781030
11.

Evaluation of two interventions to reduce the ancillary costs of outpatient care for rheumatoid arthritis.

Katz JN, Wright EA, Lynch KD, Weinblatt ME.

Arthritis Rheum. 1996 Jan;39(1):177-8. No abstract available.

PMID:
8546730

Supplemental Content

Loading ...
Support Center